Literature DB >> 12686334

Immediate and long-term clinical outcome after spinal cord stimulation for refractory stable angina pectoris.

Francesco Di Pede1, Gaetano Antonio Lanza, Guerrino Zuin, Ottavio Alfieri, Massimo Rapati, Massimo Romanò, Antonio Circo, Paola Cardano, Fulvio Bellocci, Massimo Santini, Attilio Maseri.   

Abstract

The treatment of patients with angina pectoris refractory to medical therapy and unsuitable for revascularization procedures has yet not been well standardized. Previous retrospective studies and small prospective studies have suggested beneficial effects of spinal cord stimulation (SCS) in these patients. We created a Prospective Italian Registry of SCS to evaluate the short- and long-term clinical outcome of patients who underwent SCS device implantation because of severe refractory angina pectoris. Overall, 104 patients were enrolled in the registry (70 men, aged 68 +/- 17 years), most of whom (83%) had severe coronary artery disease. Average follow-up was 13.2 +/- 8 months. Overall, 17 patients (16%) died, 8 (8%) due to cardiac death. Among clinical variables, only age was found to be significantly associated both with total mortality (p = 0.04) and cardiac mortality (p = 0.02) on Cox regression analysis. A significant improvement of anginal symptoms (> or =50% reduction of weekly anginal episodes, compared with baseline) occurred in 73% of patients, and Canadian Cardiovascular Society angina class improved by > or =1 class in 80% and by > or =2 classes in 42% of patients, with a relevant reduction in the rate of hospital admission and days spent in the hospital because of angina (p <0.0001 for both). No life-threatening or clinically serious complications were observed. The most frequent side effect consisted of superficial infections, either at the site of puncture of electrode insertion or of the abdominal pocket, which occurred in 6 patients. In conclusion, our prospective data point out that SCS can be performed safely and is associated with a sustained improvement of anginal symptoms in a relevant number of patients with refractory stable angina pectoris.

Entities:  

Mesh:

Year:  2003        PMID: 12686334     DOI: 10.1016/s0002-9149(03)00110-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Alternative treatments for angina.

Authors:  Gaetano A Lanza
Journal:  Heart       Date:  2007-05       Impact factor: 5.994

Review 2.  Spinal cord stimulation: an update.

Authors:  Steven Falowski; Amanda Celii; Ashwini Sharan
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

3.  Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised study.

Authors:  Stephan Eddicks; Klaus Maier-Hauff; Michael Schenk; Andreas Müller; Gert Baumann; Heinz Theres
Journal:  Heart       Date:  2007-01-19       Impact factor: 5.994

Review 4.  Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy.

Authors:  Jenna Dean; Sherwin Dela Cruz; Puja K Mehta; C Noel Bairey Merz
Journal:  Nat Rev Cardiol       Date:  2015-05-26       Impact factor: 32.419

Review 5.  Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

6.  Spinal Cord Stimulation for the Treatment of Angina Pectoris.

Authors:  Wilbert S. Aronow; William H. Frishman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-02

7.  Electrical neuromodulation for patients with cardiac diseases.

Authors:  K De Decker; U Beese; M J Staal; M J L Dejongste
Journal:  Neth Heart J       Date:  2013-02       Impact factor: 2.380

8.  Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial.

Authors:  M T Dyer; K A Goldsmith; S N Khan; L D Sharples; C Freeman; I Hardy; M J Buxton; P M Schofield
Journal:  Trials       Date:  2008-06-30       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.